Ultrasmall superparamagnetic iron oxide nanoparticles (USPIOs) with diameters< 5 nm hold
great promise as T 1-positive contrast agents for in vivo magnetic resonance imaging …

Although imaging‐guided drug delivery represents a noninvasive alternative to both surgical
resection and systemic methods, it has seen limited clinical use due to the potential toxicity …

Despite widespread use of conventional diagnostic methods in orthopedic applications,
limitations still exist in detection and diagnosing many pathologies, especially at early …

Ultrasmall superparamagnetic iron oxide nanoparticles (uSPIOs) are attractive platforms for
the development of smart contrast agents for magnetic resonance imaging (MRI). Oleic acid …

The introduction to the clinic of positron emission tomography‐magnetic resonance imaging
scanners opens up the possibility to evaluate the real potential of bimodal imaging agents …

Superparamagnetic nanoparticles are used as contrast agents in magnetic resonance
imaging and allow, for example, the detection of tumors or the tracking of stem cells in vivo …

Over the last decade, radiolabeled iron oxide nanoparticles have been developed as
promising contrast agents for dual‐modality positron emission tomography/magnetic …

Novel theranostic nanoplatform is expected to integrate imaging for guiding and monitoring
of the tumor therapy with great therapeutic efficacy and fewer side effects. Here we describe …

Development of efficient and rapid protocols for diversification of functional magnetic
nanoparticles (MNPs) would enable identification of promising candidates using high …

Extremely small-sized iron oxide nanoparticles (ESIONPs) with sizes less than 5 nm have
shown great promise as T 1 contrast agents for magnetic resonance imaging (MRI) …